The Effect of Different Comorbidities on Survival of Non-small Cells Lung Cancer Patients

Iachina, Maria; Jakobsen, Erik; Møller, Henrik; Lüchtenborg, Margreet; Mellemgaard, Anders; Krasnik, Mark; Green, Anders

doi:10.1007/s00408-014-9675-5

Cited by 55 publications

(65 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meta-analysis demonstrated that the presence of COPD was associated with worse clinical outcome of lung cancer 27 . Even though we and other group demonstrated that lung cancer-associated with COPD preferentially harbored somatic mutations in a few genes, the tumors from COPD and non-COPD patients exhibited highly concordant genomic alterations, which might not explain the differences in clinical outcomes between these two groups.…”

Section: Discussionmentioning

confidence: 99%

Integrative analysis of genomic sequencing data reveals higher prevalence of LRP1B mutations in lung adenocarcinoma patients with COPD

Xiao

Hui

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Both chronic Obstruction Pulmonary Disease (COPD) and lung cancer are leading causes of death globally. Although COPD and lung cancer coexist frequently, it is unknown whether lung cancer patients with COPD harbor distinct genomic characteristics compared to those without COPD. In this study, we retrospectively analyzed genomic sequencing data from 272 patients with lung adenocarcinoma (LUAD) and compared the genetic alterations in LUAD patients with and without COPD. Integrative analysis of whole-genome and exome sequencing data revealed that COPD and non-COPD groups showed high concordance in mutational burden and spectra. Notably, we also found that EGFR mutations were more prevalent in LUAD patients without COPD, whereas mutated LRP1B was more frequently observed in LUAD patients with COPD. In addition, multi-variable analysis with logistic regression demonstrated that mutation of LRP1B was a predictive marker for the presence of COPD in the patients with LUAD. Our analysis demonstrated for the first time the high concordance in genomic alterations between the tumors from LUAD patients with and without COPD. We also identified higher prevalence of LRP1B among the LUAD patients with COPD, which might help understand the underlying mechanisms which link COPD and lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Integrative analysis of genomic sequencing data reveals higher prevalence of LRP1B mutations in lung adenocarcinoma patients with COPD

Xiao

Hui

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Comorbidities occur frequently in patients with lung cancer . These comorbidities are prevalent and confer significant impacts on the prognosis . The most crucial comorbidity is COPD (chronic obstructive pulmonary disease), with a prevalence of 40% to 70% .…”

Section: Introductionmentioning

confidence: 99%

Impact of COPD and emphysema on survival of patients with lung cancer: A meta‐analysis of observational studies

et al. 2015

View full text Add to dashboard Cite

Both COPD and emphysema are associated with an increased incidence of lung cancer, but the impacts of these comorbidities on lung cancer prognosis are still unclear. Herein, we conducted a meta-analysis to clarify whether the presence of these comorbidities indicates poor survival in patients with lung cancer. A comprehensive search was conducted using PubMed, Embase, Web of Science, ASCO Abstracts and Cochrane library for articles published before 1 June 2015. Papers referenced by the obtained articles were also reviewed. Main outcomes were overall survival (OS) and disease-free survival (DFS) in patients with lung cancer. Pooled hazard ratio (HR) and 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup and sensitivity analyses were also conducted. Of 58 full texts reviewed, 26 met our inclusion criteria that were derived from 21 and seven studies examining the impacts of COPD and emphysema on survival of lung cancer, respectively. Metaanalyses revealed that concomitant COPD was associated with poorer OS (HR, 1.17; 95% CI: 1.10-1.25, n = 20), which was independent of tumour staging, diagnostic criteria of COPD or location, and DFS (HR, 1.52; 95% CI: 1.04-2.23, n = 6) with high heterogeneity (I 2 = 78%). The presence of emphysema in patients with lung cancer predicted worse OS (HR, 1.66; 95% CI: 1.25-2.22, n = 7), but not poorer DFS. The presence of COPD and emphysema are robust predictors of poor survival in patients with lung cancer. Early detection of these diseases should be taken into account for lung cancer surveillance and management.

show abstract

“…12 case‐control studies were conducted in Korea, Denmark, Japan, the United States and Spain . In terms of diagnosis of COPD, 4 studies used Spirometry, 3 studies used GOLD guideline, 2 studies used American Thoracic Society criteria or European Respiratory Society criteria, 1 studies used Spirometry and/or Computed tomography (CT), 1 studies used Medical record and 1 studies used doctor‐diagnosis …”

Section: Resultsmentioning

confidence: 99%

The prognosis of non‐small cell lung cancer combined with chronic obstructive pulmonary disease: A systematic review and meta‐analysis

Wang²,

Zhao

et al. 2020

Clinical Respiratory J

View full text Add to dashboard Cite

Objective To investigate the effect of non‐small cell lung cancer (NSCLC) combined with Chronic Obstructive Pulmonary Disease (COPD) on prognosis, so as to provide help to clinical diagnosis and treatment. Methods PubMed, Web of Science and the Medline were used to retrieve studies reported from 1950 to 2019. If the study reported the prognosis of COPD with NSCLC, the study was included and the relevant information was extracted and the data analyzed. The standard mean deviation (SMD) of 95% confidence interval was used in this meta‐analysis. Results A total of 851 data studies were reviewed for eligibility, eventually, 12 case‐control studies were included in this systematic review and meta‐analysis. The sample sizes for company's studies of NSCLC ranged from 85 to 10 378, with a total number of 14 164, including 2450 COPD and 9395 Non‐COPD. Meta‐analyses showed that concomitant COPD was associated with poorer OS compared with patients without COPD (Fixed: HR: 1.16; 95% CI: 1.08‐1.25. Random: HR: 1.07; CI: 0.92‐1.24), with a significant heterogeneity across studies (I2 = 45%, P = 0.04). Conclusion Our study showed that patients with combined COPD had an impact on the prognosis and survival rate of SCLC patients.

show abstract

The Effect of Different Comorbidities on Survival of Non-small Cells Lung Cancer Patients

Abstract: Our study shows the importance of cardiovascular disease in lung cancer. Diabetes, cerebrovascular disorders, and COPD also have a significant impact on survival of NSCLC patients.

Cited by 55 publications

References 23 publications

Integrative analysis of genomic sequencing data reveals higher prevalence of LRP1B mutations in lung adenocarcinoma patients with COPD

Integrative analysis of genomic sequencing data reveals higher prevalence of LRP1B mutations in lung adenocarcinoma patients with COPD

Impact of COPD and emphysema on survival of patients with lung cancer: A meta‐analysis of observational studies

The prognosis of non‐small cell lung cancer combined with chronic obstructive pulmonary disease: A systematic review and meta‐analysis

Contact Info

Product

Resources

About